Inhibition of Hepatitis C Virus Replication by GS-6620, a Potent C-Nucleoside Monophosphate Prodrug

ABSTRACT As a class, nucleotide inhibitors (NIs) of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase offer advantages over other direct-acting antivirals, including properties, such as pangenotype activity, a high barrier to resistance, and reduced potential for drug-drug interactions. We studied the in vitro pharmacology of a novel C-nucleoside adenosine analog monophosphate prodrug, GS-6620. It was found to be a potent and selective HCV inhibitor against HCV replicons of genotypes 1 to 6 and against an infectious genotype 2a virus (50% effective concentration [EC50], 0.048 to 0.68 μM). GS-6620 showed limited activities against other viruses, maintaining only some of its activity against the closely related bovine viral diarrhea virus (EC50, 1.5 μM). The active 5′-triphosphate metabolite of GS-6620 is a chain terminator of viral RNA synthesis and a competitive inhibitor of NS5B-catalyzed ATP incorporation, with Ki/Km values of 0.23 and 0.18 for HCV NS5B genotypes 1b and 2a, respectively. With its unique dual substitutions of 1′-CN and 2′-C-Me on the ribose ring, the active triphosphate metabolite was found to have enhanced selectivity for the HCV NS5B polymerase over host RNA polymerases. GS-6620 demonstrated a high barrier to resistance in vitro. Prolonged passaging resulted in the selection of the S282T mutation in NS5B that was found to be resistant in both cellular and enzymatic assays (>30-fold). Consistent with its in vitro profile, GS-6620 exhibited the potential for potent anti-HCV activity in a proof-of-concept clinical trial, but its utility was limited by the requirement of high dose levels and pharmacokinetic and pharmacodynamic variability.

[1]  W. Zhong,et al.  Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. , 2014, Journal of medicinal chemistry.

[2]  D. Stefanidis,et al.  Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620 , 2014, Antimicrobial Agents and Chemotherapy.

[3]  C. Rice,et al.  Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.

[4]  H. Mo,et al.  In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. , 2013, Antiviral research.

[5]  E. Schiff,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.

[6]  H. Mo,et al.  Development of robust hepatitis C virus genotype 4 subgenomic replicons. , 2013, Gastroenterology.

[7]  S. Leavitt,et al.  Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase , 2012, Antimicrobial Agents and Chemotherapy.

[8]  J. Arnold,et al.  Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides , 2012, PLoS pathogens.

[9]  H. Mo,et al.  Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. , 2012, Virology.

[10]  M. Otto,et al.  Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA , 2012, Journal of Virology.

[11]  D. Stefanidis,et al.  1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS , 2012 .

[12]  R. Monina Klevens,et al.  The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.

[13]  M. Sofia Nucleotide Prodrugs for HCV Therapy , 2011, Antiviral chemistry & chemotherapy.

[14]  C. Rice,et al.  Turning hepatitis C into a real virus. , 2011, Annual review of microbiology.

[15]  Xiaohong Liu,et al.  Preparation of HCV NS3 and NS5B Proteins to Support Small‐Molecule Drug Discovery , 2011, Current protocols in pharmacology.

[16]  K. Borroto-Esoda,et al.  HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. , 2011, Journal of virological methods.

[17]  W. Zhong,et al.  Selection of Clinically Relevant Protease Inhibitor-Resistant Viruses Using the Genotype 2a Hepatitis C Virus Infection System , 2011, Antimicrobial Agents and Chemotherapy.

[18]  W. Zhong,et al.  Novel Mutations in a Tissue Culture-Adapted Hepatitis C Virus Strain Improve Infectious-Virus Stability and Markedly Enhance Infection Kinetics , 2011, Journal of Virology.

[19]  D. Nelson The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[20]  O. Peersen,et al.  Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase , 2010, Proceedings of the National Academy of Sciences.

[21]  A. Ray,et al.  HCV NS5B polymerase inhibitors. , 2010, Current opinion in drug discovery & development.

[22]  Huiling Yang,et al.  Novel Hepatitis C Virus Reporter Replicon Cell Lines Enable Efficient Antiviral Screening against Genotype 1a , 2010, Antimicrobial Agents and Chemotherapy.

[23]  J. Arnold,et al.  Identification of Multiple Rate-limiting Steps during the Human Mitochondrial Transcription Cycle in Vitro* , 2010, The Journal of Biological Chemistry.

[24]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[25]  N. Brown Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. , 2009, Expert opinion on investigational drugs.

[26]  D. Hazuda,et al.  Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees , 2008, Antimicrobial Agents and Chemotherapy.

[27]  S. Shi,et al.  Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[28]  Blake R. Peterson,et al.  Structural Insights into Mechanisms of Catalysis and Inhibition in Norwalk Virus Polymerase* , 2008, Journal of Biological Chemistry.

[29]  Daniel Crisan,et al.  euHCVdb: the European hepatitis C virus database , 2006, Nucleic Acids Res..

[30]  Giovanni Migliaccio,et al.  A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties , 2004, Antimicrobial Agents and Chemotherapy.

[31]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[32]  Lawrence C Kuo,et al.  Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs* , 2003, The Journal of Biological Chemistry.

[33]  C. Gibbs,et al.  Biochemical characterization of rhinovirus RNA-dependent RNA polymerase. , 2002, Antiviral research.

[34]  T. Cihlar,et al.  Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[35]  K. Anderson,et al.  Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase* , 2001, The Journal of Biological Chemistry.

[36]  Alex J White,et al.  Mitochondrial toxicity and HIV therapy , 2001, Sexually transmitted infections.

[37]  Y. Tsai,et al.  Human mitochondrial DNA polymerase holoenzyme: reconstitution and characterization. , 2000, Biochemistry.

[38]  J. Silver,et al.  Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .

[39]  S. Graves,et al.  Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase. , 1998, Biochemistry.

[40]  Robert A. Copeland,et al.  Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis , 1996 .

[41]  J. H. Wang,et al.  Affinity labeling and measurement of DNA-induced conformation change in RNA polymerase II. , 1994, Biochemistry.

[42]  H. Popper American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .